Another Disappointing Year for Alzheimer’s Drugs
It’s been rough times for the development of Alzheimer’s drugs.
Last month, Myriad Genetics said its late-stage trial of its experimental drug Flurizan failed to show any benefit for Alzheimer’s patients. Another late-stage study, of Alzhemed from Canada’s Neurochem, failed last fall.
The results of the Flurizan study will be unpacked this week at a big annual Alzheimer’s conference, as researchers look at what’s next in the field, the Los Angeles Times reports this morning. Read More >>
Last month, Myriad Genetics said its late-stage trial of its experimental drug Flurizan failed to show any benefit for Alzheimer’s patients. Another late-stage study, of Alzhemed from Canada’s Neurochem, failed last fall.
The results of the Flurizan study will be unpacked this week at a big annual Alzheimer’s conference, as researchers look at what’s next in the field, the Los Angeles Times reports this morning. Read More >>
posted by Erik at
9:06 PM
© 2008 Riccardi Design, LLC
0 Comments:
Post a Comment
<< Home